Regulatory & Legal

Private lender Arixa Capital surpasses $350M in Arizona financing, fueling a housing boom. But can this growth solve the state's affordability crisis?

A pioneering, fully uncrewed mission charts deep-sea corals, aiding environmental recovery and showcasing the future of maritime technology.

The largest-ever study on school phone bans confirms huge drops in phone use and improved student well-being, but the impact on test scores is more complex.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

With new museums and unbeatable value, Memphis is evolving beyond its musical roots to become the must-visit U.S. city for 2026. Discover what's new.

Diagnostic leader Bracco enters the cell therapy market with BubbleGen, a novel microbubble tech that promises to streamline complex manufacturing.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

The WPO's 50 Fastest list reveals women-owned businesses are not just growing, they're setting new standards for innovation and economic impact.

New research reveals AI is not just hype for manufacturers. Early adopters see real value in months, leaving hesitant competitors far behind.

A new partnership aims to replace perception with performance data, allowing crypto projects to vet liquidity partners with unprecedented clarity.

A global nonprofit is championing a new front in the fight against poverty, arguing that financial aid alone isn't enough without mental health support.

Cambridge Savings is acquiring NH's First Seacoast Bancorp in a deal that expands its footprint and signals major consolidation in regional community banking.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

As federal funding for psychedelic therapy surges, practitioners warn that a critical lack of patient preparation and integration support could undermine healing.

AcreTrader's latest deal delivered big returns for investors and let a local family buy the land. Is this a new model for harmony or just a new land rush?

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

A new firm will underwrite a $400M fund, signaling a shift in patent finance toward specialized expertise and empowering small inventors.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

A novel gene therapy aims to cross the blood-brain barrier, offering new hope for Tuberous Sclerosis Complex, thanks to a powerful new partnership.